novo nordisk cvs - Search News

News

Novo missed its sales estimates on weight-loss drug Wegovy

Why Novo missed its sales estimates on weight-loss drug Wegovy: CEO

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.

Reuters on MSN · 8h

Novo Nordisk hopes to see US Wegovy sales recover soon

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

BioPharma Dive · 6d

CVS strikes Wegovy deal with Novo Nordisk

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on Thursday.

Novo Nordisk Cuts Guidance

Financial Times · 9h

Novo Nordisk cuts forecasts after replica obesity drugs hit US take-up

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions

AOL · 11h

Novo Nordisk beats on Q1 earnings, cuts 2025 outlook

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) with 99 cents per share compared to estimates of 94 cents per share. Sales of the company's blockbuster GLP-1 drugs, up 13% year-over-year, drove the quarter's results, despite a slight slowdown in weight loss sales.

The Wall Street Journal on MSN · 10h

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back its sales.

3 major takeaways from Novo Nordisk's Q1 earnings

Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations ...

Fierce Pharma8h

Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

6don MSN

CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

6don MSN

CVS Drops Lilly’s Zepbound as Preferred Drug in Win for Novo

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

7hon MSN

Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...

5don MSN

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results